Abstract:It is theorized that multivalent interaction can result in better affinity and selectivity than monovalent interaction in the design of high-performance ligands. Accordingly, biomolecular engineers are increasingly taking advantage of multivalent interactions to fabricate novel molecular assemblies, resulting in new functions for ligands or enhanced performance of existing ligands. Substantial efforts have been expended in using small molecules or epitopes of antibodies for designing multifunctional or better-performing ligands. However, few attempts to use nucleic acid aptamers as functional domains have been reported. In this study, we explore the design of bivalent nucleic acid ligands by using thrombin and its aptamers as the model by which to evaluate its functions. By assembling two thrombin-binding aptamers with optimized design parameters, this assembly has resulted in the successful development of a nucleic acid-based high-performance bivalent protein inhibitor. Our experimentation proved ( i ) that the simultaneous binding of two aptamers after linkage achieved 16.6-fold better inhibition efficiency than binding of the monovalent ligand and ( ii ) that such an improvement originated from changes in the kinetics of the binding interactions, with a k off rate ≈1/50 as fast. In addition, the newly generated aptamer assembly is an excellent anticoagulant reagent when tested with different samples. Because this optimized ligand design offers a simple and noninvasive means of accomplishing higher performance from known functional aptamers, it holds promise as a potent antithrombin agent in the treatment of various diseases related to abnormal thrombin activities.

DNA-modularized construction of bivalent ligands precisely regulates receptor binding and activation

Bivalent ligands targeting chemokine receptor dimerization: molecular design and functional studies.

Design and Synthesis of a Bivalent Ligand to Explore the Putative Heterodimerization of the Mu Opioid Receptor and the Chemokine Receptor CCR5.

Design of bivalent ligands targeting putative GPCR dimers

Molecular assembly for high-performance bivalent nucleic acid inhibitor

Programmable Assembly of Multivalent DNA‐Protein Superstructures for Tumor Imaging and Targeted Therapy

Structure-Guided Designing Pre-Organization in Bivalent Aptamers

Self‐Assembled L–DNA Linkers for Rapid Construction of Multi‐Specific Antibody‐Drug Conjugates Library

A Logical DNA-controlled Receptor Assembly for Programmable Modulation of Cellular Signal Transduction.

DNA Nanotechnology-Facilitated Ligand Manipulation for Targeted Therapeutics and Diagnostics.

Reversible control of cell membrane receptor function using DNA nano-spring multivalent ligands.

Recent Advances in the Drug Discovery and Development of Dualsteric/ Bitopic Activators of G Protein-Coupled Receptors.

A versatile strategy for convenient circular bivalent functional nucleic acids construction

Modular Construction of Multifunctional Bioresponsive Cell-Targeted Nanoparticles for Gene Delivery.

DNA-modulated dimerization and oligomerization of cell membrane receptors

Designed dualsteric modulators: A novel route for drug discovery

Programmable DNA Scaffolds Enable Orthogonal Engineering of Cell Membrane-Based Nanovesicles for Therapeutic Development

A kinetically controlled platform for ligand-oligonucleotide transduction

Tunable Multivalent Aptamer-Based DNA Nanostructures to Regulate Multiheteroreceptor-Mediated Tumor Recognition.

Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface

Engineering G-quadruplex aptamer to modulate its binding specificity